Categories Earnings, Health Care
Catabasis Pharmaceuticals (NASDAQ: CATB): Q4 2019 Earnings Snapshot
— Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) reported a net loss of $6.6 million or $0.55 per share for the fourth quarter of 2019, compared to a loss of $6.1 million or $0.85 per share last year. Analysts had forecast a loss of $0.61 per share.
— Being a development-stage biopharmaceutical company, Catabasis did nor record revenues in the December-quarter
— Research & Development expenses increased 16% year-over-year to $4.3 million during the three-month period
— At $2.5 million, selling, general and administrative expenses were up 4% from the year-ago period
— As of December 2019, cash, cash equivalents and short-term investments were $36.2 million, compared to $40.6 million as of September 2019
— Expects to fund operations through a potential NDA filing and into the third quarter of 2021, using available cash
— Expects to publish top results from the phase-3 PolarisDMD trial of edasalonexent, in Duchenne muscular dystrophy, in the fourth quarter of 2020
Most Popular
Earnings Preview: Target (TGT) expected to report lower Q3 2025 sales and profit
Target Corporation (NYSE: TGT) is navigating a challenging retail landscape ahead of next week's earnings, as sales and margins face pressure from economic uncertainty and restrained consumer demand. With a
Home Depot (HD) expected to report higher revenue and earnings in Q3 2025
Shares of The Home Depot (NYSE: HD) dipped over 1% on Monday. The stock has dropped 5% in the past three months. The home improvement retailer is scheduled to report
Tyson Foods (TSN) Q4 2025 adj. earnings beat unexpectedly; sales up 2%
Tyson Foods, Inc. (NYSE: TSN), a leading processor and marketer of chicken, beef, and pork, reported stronger-than-expected earnings for the fourth quarter of fiscal 2025 when the company's sales rose
